Evidence map›Paper›PMID 42043707›Full record

ArticleBulletin of experimental biology and medicine2026

Potential of Antioxidant and Cardioprotective Activity of a New Pyridoxine and Fumaric Acid Derivative as an Inductor of Transcription Factor Nrf2.

A A Balakina, A D Podgurskaya, V A Mumyatova, T S Stupina, T R Prikhodchenko, O S Suvorova, S V Blokhina, S Ya Gadomsky, D V Mishchenko

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A A BalakinaFederal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia. balakina@icp.ac.ru.
A D PodgurskayaFederal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
V A MumyatovaFederal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
T S StupinaFederal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
T R PrikhodchenkoFederal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
O S SuvorovaFederal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
S V BlokhinaFederal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
S Ya GadomskyFederal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
D V MishchenkoFederal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the study was to evaluate the biological activity of a new type of cardioprotectors, activators of Nrf2, based on pyridoxine and fumaric acid derivatives in vitro and in vivo. It was found that di(3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridinium) fumarate is an effective activator of Nrf2 transcription factor and exhibits cytoprotective and antioxidant activity in vitro on a cardiomyocyte model. In addition, this compound reduces the cardiotoxic effect of doxorubicin in vivo by suppressing the development of oxidative processes and activating the Nrf2-dependent antioxidant response in the heart. The studied pyridoxine and fumaric acid derivative has high potential as a candidate medication for reducing the side effects of anthracycline antibiotics, as well as for protecting heart cells in various cardiovascular diseases and age-related changes. The revealed effects are of great importance for the development of approaches to designing a new type of cardioprotective compounds, activators of the transcription factor Nrf2.

Indexed as

AntioxidantsCardiotonic AgentsFumaratesMyocytes, CardiacNF-E2-Related Factor 2PyridoxineAnimalsDoxorubicinMaleOxidative StressRatsReactive Oxygen SpeciesAntioxidantsCardiotonic AgentsDoxorubicinFumaratesfumaric acidNF-E2-Related Factor 2PyridoxineReactive Oxygen Speciescardiomyocytesheme oxygenase-1Nrf2pyridoxinereactive oxygen species

Identifiers

PMID42043707

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.